Research Training Program in Basic and Translational Oncology

描述（由申请人提供）：多学科UAB“基础和转化肿瘤学研究培训计划”专注于培养高度积极的博士前学生以及转化和基础肿瘤学领域的博士和医学博士毕业生。该计划的主要优势包括其教师的广泛专业知识和研究兴趣，包括肿瘤免疫学，癌症遗传学，癌症小鼠模型，统计遗传学，各种癌症的下一代测序，新型靶向治疗的临床前模型，以及1期和2期临床研究。在第一年，两个 博士后学员将从血液学/肿瘤学奖学金计划和在UAB进行肿瘤学研究的大量博士后研究员中挑选。他们的培训将持续三年。该培训计划将发展成为三名博士后研究员和一名 博士前学生的第二年和第三年的五年培训计划，分别。具有MD，PhD或同等终端学位的博士后学员将根据先前的学术和研究表现，推荐信和个人面试进行选择。这将包括来自医学科学家培训计划的高素质学生。虽然这是一个新的应用程序，UAB有一个积极的血液学研究培训计划，从1991年到2004年，当前癌症中心主任和前血液学/肿瘤学主任辞职。2007年任命了一位新的癌症中心主任，2008年任命了一位新的血液学/肿瘤学主任。在这一新的领导下，大量资金充足的研究人员专注于癌症研究，并加强了已经非常强大的肿瘤学研究人员核心。由于大量的教职员工参与了癌症诊断患者的护理，除了他们的研究计划，该计划提供了基础和应用肿瘤学之间的最佳接口。

DESCRIPTION (provided by applicant): The multidisciplinary UAB "Research Training Program in Basic and Translational Oncology" is focused on training highly motivated pre-doctoral students as well as PhD and MD graduates in the fields of translational and fundamental oncology. Major strengths of the program include the broad expertise and research interests of its faculty, encompassing tumor immunology, cancer genetics, mouse models of cancers, statistical genetics, next-generation sequencing of various cancers, preclinical models of novel targeted therapies, as well as phase 1 and phase 2 clinical studies. In the first year two postdoctoral trainees will be selected from the hematology/oncology fellowship program and among a large pool of postdoctoral fellows conducting oncology research at UAB. Their training will last up to three years. The training program will grow into three postdoctoral fellows and one pre-doctoral student by year two and three of the five year training program, respectively. The postdoctoral trainees with a MD, PhD or equivalent terminal degree will be selected on the basis of prior academic and research performance, letters of recommendations, and personal interviews. This will include highly qualified students from the Medical Scientist Training Program. While this is a new application, UAB had an active hematology research training program from 1991 until 2004 when the former cancer center director and the former division of hematology/oncology director resigned. A new cancer center director was appointed in 2007 and a new director of the division of hematology/oncology was appointed in 2008. Under this new leadership a large number of well-funded investigators with a focus on cancer research have been hired and strengthen an already very strong core of oncology researchers. Because a large number of the faculty members is involved in the care of patients with a diagnosis of cancer in addition to their research programs, the program offers an optimal interface between basic and applied oncology.